The only psoriasis biologic with PASI 100 as a primary endpoint in clinical trials.

SILIQ helps patients attain and retain total clearance.1,3,4

SILIQ Works Differently

First and Only IL-17
Receptor Blocker

SILIQ blocks IL-17A, IL-17C, IL-17E (IL-25) and IL-17F via their receptor to stop the proinflammatory cascade that leads to psoriasis.5

  • Blocking IL-17 Receptor A inhibits IL-17 cytokine-induced responses5

The clinical significance of these characteristics is not fully known.

IL-17 Cytokines
in Psoriasis6-8

IL-17 cytokines are key players in
the development of psoriasis. 6-8

Cytokine In Psoriasis Blocked by Receptor Complex
IL-17A Elevated 28x6 SILIQ5 IL-17RA/RC8
IL-17C Elevated 30x6 SILIQ5 IL-17RA/RE8
IL-17E (IL-25) Elevated7 SILIQ5 IL-17RA/RB9
IL-17F Elevated 33x7 SILIQ5 IL-17RA/RC8
IL-17A/F Elevated6 SILIQ5 IL-17RA/RC8

IL-17A inhibitors impede IL-17A.10,11 SILIQ blocks all of these IL-17 cytokines because it blocks interactions with the receptor that binds them: IL-17RA.5

A recent article establishes the role of IL-17C as critical in the development of psoriasis and characterizes it as the most abundant IL-17 cytokine in psoriatic lesional skin.12

IL-17 Receptor Complexes8,9

Dosing

3 injections to start, followed by 1 injection every other week 5

 

Start

Week 1

Week 2

SILIQ should be taken
once a week
for 3 weeks.

Week 3

Week 4

Week 5

Week 6

Week 7

...

After that, SILIQ should be taken once every 2 weeks. Remind your patients that consistent dosing leads to consistent results - your medicine works best when used on the right schedule

IMPORTANT ADMINISTRATION INFORMATION
  • No step down dosing
  • Dosed as a single 210-mg injection weekly for the first 3 weeks and every 2 weeks thereafter.5
  • SILIQ is supplied as a carton of two 1.5 mL (210 mg dose) pre-filled syringes.5
  • Do not inject SILIQ into area where the skin is tender, bruised, red, hard, thick, scaly, or affected by psoriasis.
  • If an adequate response to SILIQ has not been achieved within 12 to 16 weeks, consider discontinuing therapy. Continued treatment beyond 12 weeks in patients who have not achieved an adequate response is not likely to result in greater success.
  • SILIQ is a subcutaneous injection intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SILIQ when deemed appropriate by a healthcare professional and after training and subcutaneous injection technique using the pre-filled syringe. Patients should be instructed to review the Medication Guide and Instructions for Use before initiating treatment.

100% Real Stories

See how SILIQ changed the lives of patients who struggled to find lasting relief from their plaque psoriasis.

$5*

or

$25*

SILIQ Savings

Your eligible commercially insured patients can get SILIQ for as little as $5 a month, up to 12 months*. Learn how we're helping more patients go for total clearance.

*This offer is only valid for patients with commercial insurance. Patients whose commercial insurance does not cover SILIQ will pay more. These savings offers are not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B and D Plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. Click here for full eligibility terms and conditions.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Get SILIQ-certified

It’s simple. Enrolling in our REMS program takes just a few minutes.

Important Safety Information for SILIQ (brodalumab) Injection

INDICATION

SILIQ® injection is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL IDEATION AND BEHAVIOR
Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Prior to prescribing SILIQ, weigh the potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior. Patients with new or worsening suicidal ideation and behavior should be referred to a mental health professional, as appropriate. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes [see Warnings and Precautions (5.1) in the full Prescribing Information].

Because of the observed suicidal behavior in subjects treated with SILIQ, SILIQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SILIQ REMS Program [see Warnings and Precautions (5.2) in the full Prescribing Information].

Crohn’s Disease

SILIQ is contraindicated in patients with Crohn’s disease. In clinical trials, which excluded Crohn’s patients, one SILIQ patient was withdrawn after developing Crohn’s disease.

SILIQ Risk Evaluation and Mitigation Strategy (REMS) Program

SILIQ is available only through a restricted program called the SILIQ REMS because of observed suicidal ideation and behavior in patients treated with SILIQ. Before prescribing SILIQ, prescribers must be certified with the program, have each patient sign a Patient-Prescriber Agreement Form, and provide the patient a Wallet Card describing symptoms requiring immediate medical evaluation. Pharmacies must be certified and only dispense to patients authorized to receive SILIQ. More information is available at SILIQREMS.com

Infections

SILIQ may increase the risk of infections. Serious infections and fungal infections were observed at a higher rate in patients treated with SILIQ than placebo-treated patients in clinical trials, including one case of cryptococcal meningitis that led to discontinuation of therapy.

  • Consider risks and benefits prior to prescribing SILIQ in patients with a chronic infection or history of recurrent infection
  • Instruct patients to seek treatment if signs or symptoms of a chronic or acute infection occur

Risk for Latent Tuberculosis (TB) Reactivation

Evaluate patients for TB prior to initiating treatment with SILIQ and do not treat patients with active TB. Initiate treatment for latent TB prior to starting SILIQ and consider anti-TB therapy prior to initiation in patients with history of latent TB if adequate treatment cannot be confirmed. Monitor closely for symptoms of active TB during and after treatment.

Immunizations

Avoid use of live vaccines in patients treated with SILIQ.

Adverse Reactions

The most commonly reported adverse reactions in clinical trials were arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia, and tinea infections.

To report SUSPECTED ADVERSE REACTIONS, contact Customer Service at 1-800-321-4576 or the FDA at 1-800-FDA-1088, or visit www.fda.gov/MedWatch.

Click here for full Prescribing Information, including Boxed Warning about suicidal ideation and behavior.

Indication

SILIQ® may increase the risk of infections. Serious infections and fungal infections were observed at a higher rate in patients treated with SILIQ than placebo-treated patients in clinical trials, including one case of cryptococcal meningitis that led to discontinuation of therapy.

WARNING: SUICIDAL IDEATION AND BEHAVIOR

Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Prior to prescribing SILIQ, weigh the potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior. Patients with

Important Safety Information for SILIQ (brodalumab) Injection

INDICATION

SILIQ® injection is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL IDEATION AND BEHAVIOR
Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Prior to prescribing SILIQ, weigh the potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior. Patients with new or worsening suicidal ideation and behavior should be referred to a mental health professional, as appropriate. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes [see Warnings and Precautions (5.1) in the full Prescribing Information].

Because of the observed suicidal behavior in subjects treated with SILIQ, SILIQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SILIQ REMS Program [see Warnings and Precautions (5.2) in the full Prescribing Information].

Crohn’s Disease

SILIQ is contraindicated in patients with Crohn’s disease. In clinical trials, which excluded Crohn’s patients, one SILIQ patient was withdrawn after developing Crohn’s disease.

SILIQ Risk Evaluation and Mitigation Strategy (REMS) Program

SILIQ is available only through a restricted program called the SILIQ REMS because of observed suicidal ideation and behavior in patients treated with SILIQ. Before prescribing SILIQ, prescribers must be certified with the program, have each patient sign a Patient-Prescriber Agreement Form, and provide the patient a Wallet Card describing symptoms requiring immediate medical evaluation. Pharmacies must be certified and only dispense to patients authorized to receive SILIQ. More information is available at SILIQREMS.com

Infections

SILIQ may increase the risk of infections. Serious infections and fungal infections were observed at a higher rate in patients treated with SILIQ than placebo-treated patients in clinical trials, including one case of cryptococcal meningitis that led to discontinuation of therapy.

  • Consider risks and benefits prior to prescribing SILIQ in patients with a chronic infection or history of recurrent infection
  • Instruct patients to seek treatment if signs or symptoms of a chronic or acute infection occur

Risk for Latent Tuberculosis (TB) Reactivation

Evaluate patients for TB prior to initiating treatment with SILIQ and do not treat patients with active TB. Initiate treatment for latent TB prior to starting SILIQ and consider anti-TB therapy prior to initiation in patients with history of latent TB if adequate treatment cannot be confirmed. Monitor closely for symptoms of active TB during and after treatment.

Immunizations

Avoid use of live vaccines in patients treated with SILIQ.

Adverse Reactions

The most commonly reported adverse reactions in clinical trials were arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia, and tinea infections.

To report SUSPECTED ADVERSE REACTIONS, contact Customer Service at 1-800-321-4576 or the FDA at 1-800-FDA-1088, or visit www.fda.gov/MedWatch.

Click here for full Prescribing Information, including Boxed Warning about suicidal ideation and behavior.